argenx (ARGX) Competitors $605.92 +9.18 (+1.54%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARGX vs. GILD, BNTX, BIIB, MRNA, NBIX, TECH, PCVX, EXEL, QGEN, and RVMDShould you be buying argenx stock or one of its competitors? The main competitors of argenx include Gilead Sciences (GILD), BioNTech (BNTX), Biogen (BIIB), Moderna (MRNA), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Vaxcyte (PCVX), Exelixis (EXEL), Qiagen (QGEN), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry. argenx vs. Gilead Sciences BioNTech Biogen Moderna Neurocrine Biosciences Bio-Techne Vaxcyte Exelixis Qiagen Revolution Medicines Gilead Sciences (NASDAQ:GILD) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do insiders & institutionals have more ownership in GILD or ARGX? 83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, GILD or ARGX? Gilead Sciences has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Does the media favor GILD or ARGX? In the previous week, Gilead Sciences had 27 more articles in the media than argenx. MarketBeat recorded 48 mentions for Gilead Sciences and 21 mentions for argenx. Gilead Sciences' average media sentiment score of 1.15 beat argenx's score of 0.63 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 29 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenx 7 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is GILD or ARGX more profitable? Gilead Sciences has a net margin of 0.45% compared to argenx's net margin of -2.11%. Gilead Sciences' return on equity of 29.00% beat argenx's return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences0.45% 29.00% 9.83% argenx -2.11%-1.45%-1.29% Which has stronger valuation & earnings, GILD or ARGX? Gilead Sciences has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$28.30B3.97$5.67B$0.091,002.11argenx$1.86B19.49-$295.05M-$0.88-688.55 Do analysts prefer GILD or ARGX? Gilead Sciences currently has a consensus target price of $95.41, suggesting a potential upside of 5.79%. argenx has a consensus target price of $630.42, suggesting a potential upside of 4.04%. Given Gilead Sciences' higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 12 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 2.65argenx 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.91 Does the MarketBeat Community believe in GILD or ARGX? Gilead Sciences received 1826 more outperform votes than argenx when rated by MarketBeat users. Likewise, 76.90% of users gave Gilead Sciences an outperform vote while only 67.05% of users gave argenx an outperform vote. CompanyUnderperformOutperformGilead SciencesOutperform Votes246776.90% Underperform Votes74123.10% argenxOutperform Votes64167.05% Underperform Votes31532.95% SummaryGilead Sciences beats argenx on 14 of the 19 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get argenx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARGX vs. The Competition Export to ExcelMetricargenxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.23B$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.11%4.09%P/E Ratio-688.5545.50105.9717.81Price / Sales19.49392.401,247.60162.50Price / CashN/A169.3840.2336.29Price / Book8.754.597.076.50Net Income-$295.05M-$41.63M$119.40M$226.10M7 Day Performance7.39%2.46%2.16%3.98%1 Month Performance6.58%-3.49%-3.12%3.79%1 Year Performance23.15%28.32%33.73%29.31% argenx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARGXargenx2.7629 of 5 stars$605.92+1.5%$630.42+4.0%+23.2%$36.23B$1.86B-688.551,148Analyst ForecastAnalyst RevisionNews CoverageGILDGilead Sciences4.6009 of 5 stars$89.84+1.4%$95.41+6.2%+19.1%$111.96B$27.12B997.3318,000Analyst ForecastAnalyst RevisionNews CoveragePositive NewsBNTXBioNTech2.634 of 5 stars$108.20+5.9%$138.79+28.3%+15.5%$25.94B$4.13B-51.526,133Analyst ForecastBIIBBiogen4.8657 of 5 stars$158.43+1.6%$257.20+62.3%-31.7%$23.09B$9.84B14.097,570Analyst ForecastMRNAModerna4.5706 of 5 stars$38.40+4.0%$84.00+118.7%-47.4%$14.78B$6.85B-6.355,600Analyst ForecastOptions VolumeAnalyst RevisionNBIXNeurocrine Biosciences4.9714 of 5 stars$125.00+1.4%$163.91+31.1%+13.2%$12.66B$1.89B33.631,400Positive NewsTECHBio-Techne4.8614 of 5 stars$71.19+3.6%$81.78+14.9%+12.1%$11.31B$1.16B75.553,100PCVXVaxcyte3.3258 of 5 stars$88.39+2.8%$147.50+66.9%+80.7%$11.02BN/A0.00160Positive NewsHigh Trading VolumeEXELExelixis4.7968 of 5 stars$34.83+0.5%$31.44-9.7%+65.6%$9.95B$1.83B22.331,310Insider TradeAnalyst RevisionQGENQiagen4.2795 of 5 stars$42.33+0.6%$50.88+20.2%+2.1%$9.66B$1.97B108.385,967RVMDRevolution Medicines2.8269 of 5 stars$56.78-0.5%$61.00+7.4%+164.7%$9.55B$11.58M0.00443 Related Companies and Tools Related Companies GILD Alternatives BNTX Alternatives BIIB Alternatives MRNA Alternatives NBIX Alternatives TECH Alternatives PCVX Alternatives EXEL Alternatives QGEN Alternatives RVMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARGX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenx SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
